InSight Biopharmaceutical
Biosimilar and Generic Drug Development
Company Overview
Snapshot
Founded in June 1995 by Naim Tamari, InSight Biopharmaceutical operates with 11–50 employees. The company was acquired by Gencor Pacific in January 2019, marking a significant exit in its operational history.
Business overview
InSight Biopharmaceutical specializes in the development of biosimilar drugs, creating products with properties highly similar to existing approved pharmaceuticals. The company focuses on introducing these biosimilars to major markets through strategic alliances, with a portfolio spanning fertility, oncology, neurology, and rheumatology. Operating within the Health Tech & Life Sciences sector, InSight Biopharmaceutical serves the pharmaceutical industry.
Strategic signal
In January 2019, InSight Biopharmaceutical was acquired by Hong Kong's Gencor Pacific, following a period of operational challenges. This acquisition signals a consolidation within the biosimilar drug development market and highlights the strategic importance of intellectual property and market access in the pharmaceutical sector, indicating a shift in ownership and strategic direction for InSight's assets.
Company Intelligence Q&A
- What is InSight Biopharmaceutical's primary focus?
- InSight Biopharmaceutical focuses on developing biosimilar drugs with properties virtually identical to other previously approved drugs, aiming to introduce them to major markets through strategic alliances.
- When was InSight Biopharmaceutical founded?
- InSight Biopharmaceutical was founded in June 1995.
- Who is a co-founder of InSight Biopharmaceutical?
- Naim Tamari is a co-founder and CEO of InSight Biopharmaceutical.
- What was a significant event for InSight Biopharmaceutical in January 2019?
- In January 2019, InSight Biopharmaceutical was acquired by Hong Kong's Gencor Pacific, as reported by Calcalistech.com.
- What happened with InSight Biopharmaceutical in July 2017?
- In July 2017, InSight Biopharmaceutical's intellectual property and assets were sold to Estonian company PharmaEstica Manufacturing and its Israeli partner.